The doctor diagnosed him with
lymphoma.
医生诊断他患有淋巴瘤。
Lymphoma is a type of cancer that affects the lymphatic system.
淋巴瘤是一种影响淋巴系统的癌症。
She underwent chemotherapy for her non-Hodgkin's
lymphoma.
她接受了非霍奇金淋巴瘤的化疗。
Hodgkin's
lymphoma is a rare form of cancer that affects the lymph nodes.
霍奇金淋巴瘤是一种罕见的淋巴结癌。
He was in remission from his
lymphoma for several years.
他的淋巴瘤已经缓解了几年。
The symptoms of
lymphoma can include swollen lymph nodes, fatigue, and weight loss.
淋巴瘤的症状可能包括淋巴结肿大、疲劳和体重减轻。
A biopsy confirmed that the lump was indeed
lymphoma.
活组织检查确认肿块确实是淋巴瘤。
The patient is currently undergoing radiation therapy for his aggressive form of
lymphoma.
这位患者目前正在接受其侵袭性淋巴瘤的放射治疗。
Early detection and treatment are key to improving outcomes for patients with
lymphoma.
早期发现和治疗是改善淋巴瘤患者预后的关键。
There are over 60 different types of
lymphoma, each with its own unique characteristics and treatments.
有超过60种不同的淋巴瘤，每种都有其独特的特性和治疗方法。
"So far, the drug has covered major cancer types, including lymphoma, lung cancer, liver cancer, esophageal cancer and gastric cancer, benefiting millions of Chinese patients," he said.
他说：“到目前为止，该药物已涵盖主要的癌症类型，包括淋巴瘤、癌症、癌症、食管癌症和癌症，使数百万中国患者受益。”。
Chinese biotech enterprise BeiGene announced on Monday that its cancer treatment Brukinsa (zanubrutinib) has been approved by authorities in Kuwait, Bahrain and Qatar for the treatment of adult patients with mantle cell lymphoma who have received at least one prior therapy.
中国生物技术企业百济基因周一宣布，其癌症治疗药物Brukinsa（zanubrutinib）已获得科威特、巴林和卡塔尔当局的批准，用于治疗至少接受过一次治疗的成年套细胞淋巴瘤患者。
In November 2019, Brukinsa was approved by the US Food and Drug Administration to treat mantle cell lymphoma in adult patients, marking the first cancer treatment developed in China to be approved for the US market.
2019年11月，Brukinsa获得美国食品药品监督管理局批准，用于治疗成年患者的套细胞淋巴瘤，这标志着中国开发的第一种癌症治疗方法获准进入美国市场。
Biopharmaceutical companyxa0Pfizer announced on Friday that Lorbrena, the world's first third-generation anaplastic lymphoma kinase inhibitor, has been approved by China's National Medical Products Administration for the treatment of patients with ALK-positive locally advanced or metastatic non-small cell lung cancer.
生物制药公司xa0Pfizer周五宣布，世界上第一种第三代间变性淋巴瘤激酶抑制剂Lorbrena已被中国国家药品监督管理局批准用于治疗ALK阳性的局部晚期或转移性癌症患者。
Through this collaboration, Roche Pharma China will further enrich the hematology portfolio, expand the panorama of lymphoma treatment and continue to work together to promote the standardization of lymphoma treatment in China.
通过此次合作，罗氏制药中国公司将进一步丰富血液学产品组合，扩大淋巴瘤治疗的全景，并继续共同努力，促进中国淋巴瘤治疗的标准化。
The drug by Teva was approved in China in 2018, and is the first original product marketed by Teva for the treatment of inert B-cell non-Hodgkin's lymphoma.
Teva的药物于2018年在中国获批，是Teva销售的第一款用于治疗惰性B细胞非霍奇金淋巴瘤的原创产品。
The two companies said that the collaboration will provide a foundation for a combined medication of the drug and two by Roche to create better survival benefits for Chinese lymphoma patients.
两家公司表示，此次合作将为该药物和罗氏公司的两种药物的联合用药奠定基础，为中国淋巴瘤患者创造更好的生存效益。
The five-year survival rate of lymphoma patients in China is 39 percent, compared with about 70 percent in developed countries.
中国淋巴瘤患者的五年生存率为39%，而发达国家约为70%。
The tablet is a new anaplastic lymphoma kinase (ALK) tyrosine kinase inhibitor used to treat those suffering from non-small cell lung cancer.
该片是一种新型间变性淋巴瘤激酶（ALK）酪氨酸激酶抑制剂，用于治疗癌症患者。
In recent years, CAR-T cell therapy has achieved great success in the field of lymphoma.
近年来，CAR-T细胞治疗在淋巴瘤领域取得了巨大成功。
It is even challenging the supremacy of autologous stem-cell transplantation, which has been a key course of treatment for lymphoma in the past few decades.
它甚至挑战了自体干细胞移植的霸主地位，在过去几十年里，自体干细胞植入一直是淋巴瘤的关键治疗过程。
For example, patients with relapsed/refractory diffuse large B-cell lymphoma (R/R DLBCL) have achieved better survival benefits after receiving ASCT combined with CAR-T therapy.
例如，复发/难治性弥漫性大B细胞淋巴瘤（R/R-DLBCL）患者在接受ASCT联合CAR-T治疗后，获得了更好的生存益处。
ASCT is currently a critical treatment for lymphoma, but what would the efficacy be if it is combined with the promising CAR-T therapy?
ASCT目前是淋巴瘤的关键治疗方法，但如果它与有前景的CAR-T疗法相结合，疗效会如何？
Professor Zhou Jianfeng, director of the Department of Hematology at Tongji Hospital, Tongji Medical College of Huazhong University of Science and Technology, together with his team members, has applied the innovative combination of traditional autologous hematopoietic stem-cell transplantation with CAR-T therapy to the treatment of relapsed and refractory lymphoma.
华中科技大学同济医学院同济医院血液科主任周剑锋教授携团队成员，将传统自体造血干细胞移植与CAR-T疗法的创新结合应用于复发难治性淋巴瘤的治疗。
The study indicated that lymphoma develops a complex immunosuppressive microenvironment, which may prevent CAR-T from continuously targeting tumors.
研究表明，淋巴瘤发展出复杂的免疫抑制微环境，这可能会阻止CAR-T持续靶向肿瘤。
For lymphoma affecting the central nervous system in particular, the Department of Hematology of Tongji Hospital has led another clinical trial, specifically targeting in the long-term cure of patients in advanced stages and with CNS invasion after receiving the combined treatment of autologous hematopoietic stem-cell transplantation and CAR-T for the first time in the world.
特别是对影响中枢神经系统的淋巴瘤，同济医院血液科领导了另一项临床试验，专门针对在世界上首次接受自体造血干细胞移植和CAR-T联合治疗后，长期治愈晚期和中枢神经系统侵犯的患者。
In the past few decades, autologous hematopoietic stem-cell transplantation has played a fundamental role in the treatment of lymphoma.
在过去的几十年里，自体造血干细胞移植在淋巴瘤的治疗中发挥了基础性作用。
Therefore, the medical community expects that the combination of ASCT and CAR-T can bring more treatment options and benefits to patients with lymphoma.
因此，医学界期待ASCT和CAR-T的结合能为淋巴瘤患者带来更多的治疗选择和益处。
Case sharing: Combination of ASCT and CAR-T therapy improves CNS lymphoma patient survival benefitsOn Dec 21, Wu, a 52 years old woman, who suffered from DLBCL with multiple parts of the brain affected, received autologous hematopoietic stem-cell transplantation combined with CAR-T therapy at Tongji Hospital of Huazhong University of Science and Technology.
案例分享：ASCT和CAR-T联合治疗提高中枢神经系统淋巴瘤患者生存率12月21日，吴，一名52岁的女性，患有DLBCL，大脑多个部位受到影响，在华中科技大学同济医院接受了自体造血干细胞移植和CAR-T联合治疗。
Chief physician Meng Fankai, a member of the Tongji CAR-T therapy team, said, "As a typical case of lymphoma involving the central nervous system, Wu received six cycles of chemotherapy in the local hospital and developed memory impairment.
同济CAR-T治疗团队成员孟凡凯主任医师说：“作为中枢神经系统淋巴瘤的典型病例，吴在当地医院接受了六个周期的化疗，并出现了记忆障碍。
With large-scale promotion and application of this therapy in the future, it will be possible to offer new options to save patients suffering from lymphoma.
随着这种疗法在未来的大规模推广和应用，将有可能为挽救淋巴瘤患者提供新的选择。
Zhao discussed the treatment of two diffuse large B-cell lymphoma patients in China who received CAR-T cell therapy.
赵教授讨论了中国两位接受CAR-T细胞疗法治疗的弥漫性大B细胞淋巴瘤患者的情况。
Through a comprehensive presentation of patient characteristics, treatment process, adverse events management post CAR-T, and efficacy assessment, she demonstrated the outstanding efficacy of CAR-T for the treatment of lymphoma, the valuable Chinese experience in the whole process of CAR-T management, as well as current challenges and effective strategies to tackle them.
她通过全面展示患者特征、治疗流程、CAR-T疗法后的不良事件管理以及疗效评估，证明了CAR-T疗法在淋巴瘤治疗中的显著疗效，展现了中国在整个CAR-T管理过程中的宝贵经验，同时也指出了当前面临的挑战及应对这些挑战的有效策略。
The company's oral drug Selinexor, which works in a mechanism different from all existing approved therapies, was approved on July 29 in South Korea, the first overseas market in Asia, to treat relapsed/refractory multiple myeloma and relapsed/refractory diffuse large B-cell lymphoma, a form of cancer.
该公司的口服药物Selinexor采用了与所有现有批准疗法不同的机制，于7月29日在亚洲首个海外市场韩国获得批准，用于治疗复发/难治性多发性骨髓瘤和复发/难治性弥漫性大B细胞淋巴瘤，这是一种癌症形式。
On July 29, the company's oral drug Selinexor, which works in a mechanism different from all the existing approved therapies, was approved in South Korea, the first overseas market in Asia, to treat relapsed/refractory multiple myeloma and relapsed/refractory diffuse large B-cell lymphoma.
在7月29日，该公司研发的口服药物Selinexor获得批准，在亚洲首个海外市场——韩国上市，用于治疗复发/难治性多发性骨髓瘤和复发/难治性弥漫大B细胞淋巴瘤。这款药物的作用机制与现有所有已获批疗法均不相同。
The drug, co-developed by Eli Lilly and Innovent, was actually approved by the National Medical Products Administration to treat classical Hodgkin's lymphoma as its first indication in December 2018, and was the first PD-1 inhibitor to be involved in the country's national reimbursement drug list.
这款药物由礼来和信达生物共同开发，实际上在2018年12月就已经获得国家药品监督管理局批准，用于治疗经典型霍奇金淋巴瘤，也是中国首个被纳入国家医保药品目录的PD-1抑制剂。
In November 2019, the drug received accelerated approval in the US to treat mantle cell lymphoma in adult patients.
2019年11月，该药物在美国获得加速批准，用于治疗成年患者的套细胞淋巴瘤。
In June, BeiGene's drug Brukinsa received conditional approval in China as a treatment for adult patients with chronic lymphocytic leukemia or small lymphocytic lymphoma who have received at least one prior therapy, and as a treatment for adult patients with MCL who have received at least one prior therapy.
今年6月， BeiGene的药物Brukinsa在中国获得有条件批准，用于治疗至少接受过一次治疗的成年慢性淋巴细胞白血病或小淋巴细胞淋巴瘤患者，以及至少接受过一次治疗的成年MCL患者。
It received approval from the China National Medical Products Administration in December for the treatment of certain types of lymphoma, after being previously granted priority review by the Center for Drug Evaluation of the NMPA.
它在12月获得了中国国家药品监督管理局的批准，用于治疗某些类型的淋巴瘤，此前该药物已获得NMPA药品评价中心的优先审查。
Lymphoma, a malignant tumor that originates from the lymphoid hematopoietic system, is one of the top 10 malignant tumors with the highest mortality rates in China.
淋巴瘤是一种起源于淋巴造血系统的恶性肿瘤，是中国死亡率最高的十大恶性肿瘤之一。
The drug is for the treatment of adult patients with mantle cell lymphoma who have received at least one prior therapy, and also for adult patients with chronic lymphocytic leukemia or small lymphocytic lymphoma.
这款药物适用于已经接受过至少一次先前治疗的成年弥漫性大B细胞淋巴瘤患者，以及成年慢性淋巴细胞白血病或小淋巴细胞淋巴瘤患者。
The drug is paired with Merck Sharp& Dohme Corp's Keytruda for solid tumors and Biogen and Genentech's Rituxan for non-Hodgkin lymphoma in the ongoing US studies.
BeiGene, a Beijing-based commercial-stage biotechnology company, announced on Wednesday the approval of a self-developed lymphoma drug from thexa0National Medical Products Administration, marking China's first self-developed BTK inhibitor — a cancer treatment — coming into the market.
The drug received accelerated approval from thexa0US Food and Drug Administration as a treatment for mantle cell lymphoma in adult patients who have received at least one prior therapy inxa0November 2019.
"The approval of the drug will provide an important treatment option for Chinese patients with lymphoma.
The drug is also the first self-developed cancer drug recommended by both the lymphoma treatment plan issued by the Chinese Society of Clinical Oncology and the United States National Comprehensive Cancer Network guidelines.
Zhu Jun, professor and director of thexa0department of internal medicine and lymphoma at Peking University Cancer Hospital said: "The drug's approval in both China and the US is encouraging for Chinese biopharmaceutical firms.
The USFDA's accelerated approval for BeiGene's Brukinsa (zanubrutinib) capsules, for the treatment of adult patients with mantle cell lymphoma who have received at least one prior therapy, received positive media coverage in China and elsewhere.
In November, Chinese biomedicine company BeiGene Ltd's cancer treatment Brukinsa (zanubrutinib) capsules gained Accelerated Approval by the FDA under a Breakthrough Therapy designation to treat Mantle Cell lymphoma.
According to their agreement, they will jointly carry out the phase-3 study to access the safety and efficacy of lisaftoclax (APG-2575), an investigational drug developed by Ascentage Pharma, as first-line treatment in combination with AstraZeneca's Calquence (acalabrutinib) for chronic lymphocytic leukemia or small lymphocytic lymphoma patients who have not received any treatment.
The new drug, which was approved in China to treat classical Hodgkin's lymphoma as its first indication in late 2018, became the No 1 product for Lilly China for the past two years, replacing a diabetes insulin drug that had remained No 1 for two decades.
这款新药在2018年底获准在中国用于治疗经典霍奇金淋巴瘤，这是其在中国的第一个适应症。在过去两年中，该药已成为礼来中国的第一大产品，取代了一款连续20年保持第一的糖尿病胰岛素药物。
The drug treats adult patients with mantle cell lymphoma.
该药物用于治疗成人 mantle 细胞淋巴瘤患者。
In April, China's National Medical Products Administration approved the company's anti-PD-1 antibody tislelizumab as a treatment for patients with locally advanced or metastatic urothelial carcinoma, the most common type of bladder cancer, following the therapy's initial approval in classic Hodgkin's lymphoma in December 2019.
在4月，中国国家药品监督管理局批准了该公司的抗PD-1抗体tislelizumab用于治疗局部晚期或转移性尿路上皮癌（最常见的膀胱癌）的患者，此前该疗法于2019年12月首次被批准用于经典霍奇金淋巴瘤。
In July 2020, Brukinsa was approved by the NMPA for two indications-mantle cell lymphoma and chronic lymphocytic leukemia.
In July 2020, Brukinsa was approved by the NMPA for two indications-mantle cell lymphoma and chronic lymphocytic leukemia.'的中文翻译为：'2020年7月，布鲁金莎被NMPA批准用于两种适应症- mantle细胞淋巴瘤和慢性淋巴细胞性白血病。
The China National Medical Products Administration announced on Saturday that the Chinese pharmaceutical company BeiGene Ltd's anti-PD-1 antibody tislelizumab had received its approval as a treatment for patients with classical Hodgkin's lymphoma who have received at least two prior therapies under priority review.
The FDA announced on Friday Beijing time its Accelerated Approval of the drug for treatment of adult patients with mantle cell lymphoma who have received at least one prior therapy, based on the overall response rate or how many patients experience a complete or partial shrinkage of their tumors after treatment.
Mantle cell lymphoma, or MCL, is a rare, aggressive form of non-Hodgkin's lymphoma, a cancer originating from the white blood cell called "lymphoma".
In the US, MCL represents 3 to 10 percent of all non-Hodgkin's lymphoma, and usually responds well to initial treatment, but eventually returns or stops responding as cancer cells continue to grow, according to the FDA announcement.
New drug applications to China's National Medical Products Administration for relapsed or refractory MCL in August 2018, and for relapsed or refractory chronic lymphocytic leukemia or small lymphocytic lymphoma, later in October 2018, have been accepted and granted priority review.
The United States Food and Drug Administration announced on Thursday it would grant accelerated approval to Chinese biomedicine company BeiGene Ltd's Brukinsa (zanubrutinib) capsules, for the treatment of adult patients with mantle cell lymphoma who have received at least one prior therapy.
Mantle cell lymphoma, or MCL, is a rare, aggressive form of non-Hodgkin's lymphoma, which is a cancer developing from lymphocytes, a type of white blood cell.
In the US, MCL represents 3 to 10 percent of all non-Hodgkin's lymphoma.
In relapsed lymphoma, the disease reappears or grows again after a period of remission, while in refractory lymphoma, the disease does not respond to treatment or responds only briefly,according to FDA's press announcement.
In May 2019, an anti-PD-1 medicine developed by Hengrui Medicine Co Ltd got approval from the National Medical Products Administration for treating Hodgkin lymphoma, becoming China's third homegrown PD-1 treatment.
In December 2018, China's first homegrown PD-1 treatment, developed by Shanghai Junshi Biosciences Co Ltd, was conditionally approved by the administration under priority review for treating skin cancer melanoma, followed by the approval of another PD-1 medicine a few days later for treating Hodgkin lymphoma, which was developed by Innovent Biologics Inc.
Another example was Fosun Pharma's holding subsidiary Shanghai Henlius Biotech Inc's biosimilar version of a popular biologic original for lymphoma treatment by Roche.
Tislelizumab received approval from the China National Medical Products Administration last April as a treatment for patients with locally advanced or metastatic urothelial carcinoma, the most common type of bladder cancer, following the therapy's initial approval in classical Hodgkin's lymphoma by the NMPA in December 2019.
China's biotechnology company BeiGene Ltd announced on Saturday that its anti-PD-1 antibody tislelizumab, an immunotherapy, had received approval from the China National Medical Products Administration as a treatment for patients with locally advanced or metastatic urothelial carcinoma (UC), the most common type of bladder cancer, following the therapy's initial approval in classical Hodgkin's lymphoma by the NMPA in December.
The company also has a broad development program for tislelizumab that encompasses 15 potentially registration-enabling trials globally and in China, in indications including lung, liver, esophageal, gastric, nasopharyngeal, and MSI-H or dMMR cancers, in addition to classical Hodgkin's lymphoma and UC.
The prospectus shows that Chidamide, which is used for peripheral T-cell lymphoma, contributed about 99 percent to the annual income of Chipscreen Biosciences.
未经许可，严禁转发。QQ交流群：688169419